Showing 4041-4050 of 5957 results for "".
- Centricity Vision to Present at ASCRS and Eyeceleratorhttps://modernod.com/news/centricity-vision-to-present-at-ascrs-and-eyecelerator/2482203/Centricity Vision announced that it will present on its recently launched ZEPTOLink IOL Positioning System during the 2024 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting to be held April 5-8, 2024 in Boston. Additionally, Leonard Borrmann, the company’s newl
- Nordic Pharma to Present Data on Lacrifill Canaliocular Gel, a Novel Therapy for Dry Eye, at ASCRShttps://modernod.com/news/nordic-pharma-to-present-data-on-lacrifill-canaliocular-gel-a-novel-therapy-for-dry-eye-at-ascrs/2482202/Nordic Pharma will be presenting data on Lacrifill Canalicular Gel, a novel therapy for dry eye symptoms, during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Boston, on April 5-8, 2024. Lacrifill Canalicular Gel is a cross-linked hyaluronic acid derivativ
- Haag-Streit Launches Eyesi Indirect Ophthalmoscope ROP Simulator for Retinal Examinations on Preterm Infantshttps://modernod.com/news/haag-streit-launches-eyesi-indirect-ophthalmoscope-rop-simulator-for-retinal-examinations-on-preterm-infants/2482200/Haag-Streit has launched the Eyesi Indirect Ophthalmoscope ROP Simulator for training of retinal examinations on premature babies and classification of retinopathy of prematurity (ROP). The high-fidelity training system is designed to allow residents to practice device handling and
- Pantheon Vision Secures a Second Tranche of Funding to Advance Bioengineered Corneal Implantshttps://modernod.com/news/pantheon-vision-secures-a-second-tranche-of-funding-to-advance-bioengineered-corneal-implants/2482197/Pantheon Vision, a pre-clinical stage medical device company developing bioengineered corneal implants, announced the closing of $1.8 million in a second tranche from KeraLink International (KLI). This comes following a previous $2.5 million investment from KLI last year, bringing the total
- Staar Surgical Celebrates Milestone and Unveils New EVO ICL Data at ASCRShttps://modernod.com/news/staar-surgical-celebrates-milestone-and-unveils-new-evo-icl-data-at-ascrs/2482194/At the ASCRS annual meeting in Boston, April 5-8, 2024, Staar Surgical will be celebrating a commercial milestone: 3 million lenses sold. Staar will be showcasing the clinical, practice and innovation advantages of the EVO ICL through a series of posters, presentations and educational p
- Regenxbio Announces Lancet Publication of Phase 1/2a Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMDhttps://modernod.com/news/regenxbio-announces-lancet-publication-of-phase-12a-study-evaluating-abbv-rgx-314-as-a-one-time-gene-therapy-for-wet-amd/2482186/Regenxbio announced the publication of results from the phase 1/2a trial evaluating the safety and tolerability of a single dose of subretinal ABBV-RGX-314 for the treatment of wet age-related macular degeneration (AMD). Two-year data were
- Azura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseaseshttps://modernod.com/news/azura-ophthalmics-to-present-new-data-supporting-the-potential-of-azr-md-001-to-be-the-first-ophthalmic-keratolytic-for-ocular-surface-diseases/2482185/Azura Ophthalmics announced multiple presentations highlighting positive efficacy and safety data from phase 2 studies of the company’s lead drug candidate, AZR-MD-001, in meibomian gland dysfunction (MGD). This includes new, long-term data at ASCRS of the company’s lead drug candidat
- Nanoscope Announces Topline Results from Phase 2b Trial of MCO-010 for Retinitis Pigmentosahttps://modernod.com/news/nanoscope-announces-topline-results-from-randomized-phase-2b-trial-of-mco-010-for-retinitis-pigmentosa/2482183/Nanoscope Therapeutics announced positive topline results after the completion of the 2-year phase 2b RESTORE randomized, controlled clinical trial of its lead program, MCO-010, a mutation-agnostic gene therapy for patients with permanent and severe vision loss from advanced retini
- Opus Genetics Completes Dosing in First Cohort of Phase 1/2 Trial of Gene Therapy OPGx-LCA5https://modernod.com/news/opus-genetics-completes-dosing-in-first-cohort-of-phase-12-trial-of-gene-therapy-opgx-lca5-in-patients-with-lca5/2482180/Opus Genetics announced that the first cohort has completed dosing in its open-label, dose-escalation phase 1/2 clinical trial evaluating the subretinal delivery of OPGx-LCA5, an adeno-associated virus 8 (AAV8) vector designed to precisely deliver a functional LCA5 gene to the oute
- GenSight Biologics Confirms Sustained Efficacy and Safety of Lumevoq Injections 4 Years After One-Time Administrationhttps://modernod.com/news/gensight-biologics-confirms-sustained-efficacy-and-safety-of-lumevoq-injections-4-years-after-one-time-administration/2482174/GenSight Biologics reported initial efficacy and safety results at 4 years post-treatment administration in the REFLECT phase 3 clinical trial with Lumevoq (GS010; lenadogene nolparvovec). The results show that 4 years after a one-ti